| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d6a412a5d1b2dbe3cee616dbc52e1489 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-64
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-41
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-526 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P21-005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-46 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-07
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-46 |
| filingDate |
2013-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2016-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3e03b3504b1cc6dfb403963ddf811691
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9ddf54865e77fff4e38b301ddb5fa936
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0be779514818afac51f783739661a17 |
| publicationDate |
2016-11-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9499634-B2 |
| titleOfInvention |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells |
| abstract |
The present invention provides a process and methods for producing asymmetric antibodies in a mammalian expression system. The asymmetric antibodies are transiently or stably expressed and in cells that stably express the asymmetric antibody, following a rapid 2-step process of stable pool to clone, a highly pure asymmetric antibody expressing clone can be identified at a success frequency that permits for screening of tens of clones rather than thousands. The asymmetric antibodies are produced at a high titre and with a high level of purity with no contaminating homodimer antibodies following protein A purification with a step yield of near 100%. Typical downstream purification processes employ standard hydrophobic interaction chromatography (HIC) and/or cation exchange (CEX) resins and the antibody is stable within a wide dynamic range of buffer pH (4-8) and within the requirements for manufacturing antibodies for pre-clinical and clinical applications. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11091527-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11091526-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11466068-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10077298-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019122409-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10508154-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11325981-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10239951-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11739146-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11306156-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11078296-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10875931-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10947295-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11739160-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11779632-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10946068-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10000576-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10457742-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10947319-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10961310-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11286293-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9771573-B2 |
| priorityDate |
2012-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |